{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:25:21Z","timestamp":1785774321616,"version":"3.56.0"},"reference-count":156,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Several decades have passed since the description of the first patient with primary aldosteronism (PA). PA was initially classified in two main forms: aldosterone-producing adenoma (APA) and idiopathic hyperaldosteronism (IHA). However, the pathogenesis of PA has now been shown to be far more complex. For this reason, the traditional classification needs to be updated. Given the recent advancements in our understanding of PA pathogenesis, we should reevaluate how frequent PA cases are, beginning with the reconstruction of the screening strategy. Recent studies consistently indicated that PA has been identified in 22% of patients with resistant hypertension and 11% even in normotensives. The frequency is influenced by the screening strategy and should be based on understanding the pathogenesis of PA. Progress has been made to promote our understanding of the pathogenesis of PA by the findings of aldosterone driver mutations, which have been found in normotensives and hypertensives. In addition, much clinical evidence has been accumulated to indicate that there is a spectrum in PA pathogenesis. In this review, we will summarize the recent progress in aldosterone measurement methods based on LC-MS\/MS and the current screening strategy. Then, we will discuss the progress of our understanding of PA, focusing on aldosterone driver mutations and the natural history of PA. Finally, we will discuss the optimal strategy to improve screening rate and case detection.<\/jats:p>","DOI":"10.3389\/fendo.2024.1372683","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T05:10:31Z","timestamp":1736831431000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Shifting paradigms in primary aldosteronism: reconsideration of screening strategy via integrating pathophysiological insights"],"prefix":"10.3389","volume":"15","author":[{"given":"Takumi","family":"Kitamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Ruike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Koide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Maezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Omura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Tsurutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Kuwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutaro","family":"Yokote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"B1","article-title":"Primary aldosteronism","volume":"45","author":"Conn","year":"1955","journal-title":"J Lab Clin Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03090030022005","article-title":"Normokalemic primary aldosteronism. A detectable cause of curable \u201cEssential\u201d Hypertension","volume":"193","author":"Conn","year":"1965","journal-title":"JAMA."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Internal Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol Jan"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1981.00340130033011","article-title":"A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity: results in hypertensive patients","volume":"141","author":"Hiramatsu","year":"1981","journal-title":"Arch Internal Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2017.06.004","article-title":"Case detection and diagnosis of primary aldosteronism - The consensus of Taiwan Society of Aldosteronism","volume":"20","author":"Wu","year":"2017","journal-title":"J Formos Med Assoc"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/HYP.0000000000000065","article-title":"ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"71","author":"Whelton Paul","year":"2017","journal-title":"Hypertension"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"B13","article-title":"Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension\u2217","volume":"38","author":"Mulatero","year":"2020","journal-title":"J Hypertension."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijchy.2020.100029","article-title":"The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism","volume":"5","author":"Rossi","year":"2020","journal-title":"Int J Cardiol Hypertension."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.ej21-0508","article-title":"Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021","volume":"69","author":"Naruse","year":"2022","journal-title":"Endocrine J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001013","article-title":"High prevalence of primary aldosteronism in the Tayside hypertension clinic population","volume":"14","author":"Lim","year":"2000","journal-title":"J Hum Hypertens May"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.8.2854","article-title":"Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. Article","volume":"85","author":"Loh","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/s0895-7061(02)02969-2","article-title":"High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives","volume":"15","author":"Rossi","year":"2002","journal-title":"Am J Hypertens"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000079505.25750.11","article-title":"Primary aldosteronism and hypertensive disease","volume":"42","author":"Mosso","year":"2003","journal-title":"Hypertension. Aug"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200311000-00025","article-title":"High rate of detection of primary aldosteronism, including surgically treatable forms, after \u2018non-selective\u2019 screening of hypertensive patients","volume":"21","author":"Stowasser","year":"2003","journal-title":"J Hypertens"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001554","article-title":"Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region","volume":"17","author":"Strauch","year":"2003","journal-title":"J Hum Hypertens"},{"key":"B22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1291\/hypres.27.193","article-title":"Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan","volume":"27","author":"Omura","year":"2004","journal-title":"Hypertens Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2005.01.002","article-title":"Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension","volume":"18","author":"Nishizaka","year":"2005","journal-title":"Am J Hypertens"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.30.111","article-title":"Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone\/renin ratio above 25 as a screening test","volume":"30","author":"Fogari","year":"2007","journal-title":"Hypertens Res Feb"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60834-X","article-title":"Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study","volume":"371","author":"Douma","year":"2008","journal-title":"Lancet Jun 7"},{"key":"B26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/02813432.2011.554015","article-title":"Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area","volume":"29","author":"Westerdahl","year":"2011","journal-title":"Scand J Prim Health Care"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-12-17","article-title":"Unilateral adrenal hyperplasia is a usual cause of primary hyperaldosteronism","volume":"12","author":"Sigurjonsdottir","year":"2012","journal-title":"Results Swedish screening study. BMC Endocr Disord"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328360ddf6","article-title":"Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China","volume":"31","author":"Sang","year":"2013","journal-title":"J Hypertens"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4158\/E161332.OR","article-title":"Prevelence of primary aldosteronism in an urban hypertensive population","volume":"22","author":"Galati","year":"2016","journal-title":"Endocr Pract Nov"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp18X694589","article-title":"Prevalence of primary aldosteronism in primary care: a cross-sectional study","volume":"68","author":"Kayser","year":"2018","journal-title":"Br J Gen Pract"},{"key":"B32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: A cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.02.052","article-title":"Primary aldosteronism in patients in China with recently detected hypertension","volume":"75","author":"Xu","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2020.10.007","article-title":"Prevalence, subtype classification, and outcomes of treatment of primary aldosteronism: A prospective study in China","volume":"27","author":"Xu","year":"2021","journal-title":"Endocr Pract"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1055\/a-1938-4242","article-title":"Prevalence of primary aldosteronism in newly diagnosed hypertensive patients in primary care","volume":"130","author":"Asbach","year":"2022","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-00948-7","article-title":"Prevalence and clinical characteristics of primary aldosteronism in a tertiary-care center in Korea","volume":"45","author":"Yoon","year":"2022","journal-title":"Hypertens Res"},{"key":"B37","article-title":"Prevalence of primary aldosteronism in patient\u2019s cohorts and in population-based studies\u2013a review of the current literature","volume":"44","author":"Hannemann","year":"2012","journal-title":"Horm Metab Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1161\/circoutcomes.115.002002","article-title":"Cost-effectiveness of screening for primary aldosteronism and subtype diagnosis in the resistant hypertensive patients","volume":"8","author":"Lubitz","year":"2015","journal-title":"Circulation: Cardiovasc Qual Outcomes."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1559645","article-title":"Cost-effectiveness analysis of the diagnosis and treatment of primary aldosteronism in Japan","volume":"47","author":"Sato","year":"2015","journal-title":"Horm Metab Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/hjh.0000000000003513","article-title":"Cost-effectiveness of screening for primary aldosteronism in hypertensive patients in Australia: a Markov modelling analysis","volume":"41","author":"Woode","year":"2023","journal-title":"J Hypertension."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.119.14359","article-title":"Screening rates for primary aldosteronism in resistant hypertension","volume":"75","author":"Jaffe","year":"2020","journal-title":"Hypertension."},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.7326\/M20-4873","article-title":"Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among US veterans: a retrospective cohort study","volume":"174","author":"Cohen","year":"2021","journal-title":"Ann Internal Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamasurg.2021.0254","article-title":"Outcomes of a specialized clinic on rates of investigation and treatment of primary aldosteronism","volume":"156","author":"Liu","year":"2021","journal-title":"JAMA Surgery."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.121.18118","article-title":"Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: A population-based retrospective cohort study","volume":"79","author":"Hundemer","year":"2022","journal-title":"Hypertension."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004022.pub5","article-title":"Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride","volume":"12","author":"Graudal","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-28-7-1014","article-title":"Effects of glucocorticoid administration on aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism","volume":"28","author":"Newton","year":"1968","journal-title":"J Clin Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/0039-128x(96)00007-4","article-title":"Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure","volume":"61","author":"Oelkers","year":"1996","journal-title":"Steroids."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2603","article-title":"Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone\/renin ratio in normotensive depressed male patients","volume":"96","author":"Ahmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1210\/er.2017-00054","article-title":"Screening for endocrine hypertension: an endocrine society scientific statement","volume":"38","author":"Young","year":"2017","journal-title":"Endocrine Rev"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00210-2","article-title":"Diagnosis and treatment of primary aldosteronism","volume":"9","author":"Reincke","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2015.01.003","article-title":"Laboratory challenges in primary aldosteronism screening and diagnosis","volume":"48","author":"Rehan","year":"2015","journal-title":"Clin Biochem"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz150","article-title":"Diagnosis of primary aldosteronism by seated saline suppression test\u2014Variability between immunoassay and HPLC-MS\/MS","volume":"105","author":"Thuzar","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253807","article-title":"Comparisons of plasma aldosterone and renin data between an automated chemiluminescent immunoanalyzer and conventional radioimmunoassays in the screening and diagnosis of primary aldosteronism","volume":"16","author":"Tamura","year":"2021","journal-title":"PloS One"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.ej16-0304","article-title":"Calibration and evaluation of routine methods by serum certified reference material for aldosterone measurement in blood","volume":"63","author":"Nishikawa","year":"2016","journal-title":"Endocrine J"},{"key":"B55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1507\/endocrj.ej21-0278","article-title":"Comparison and commutability study between standardized liquid chromatography-mass spectrometry\/mass spectrometry (LC-MS\/MS) and chemiluminescent enzyme immunoassay for aldosterone measurement in blood","volume":"69","author":"Nishikawa","year":"2022","journal-title":"Endocrine J"},{"key":"B56","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1530\/eje-20-0030","article-title":"Prospective evaluation of aldosterone LC-MS\/MS-specific cutoffs for the saline infusion test","volume":"183","author":"Fries","year":"2020","journal-title":"Eur J Endocrinology."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01041","article-title":"Aldosterone LC-MS\/MS assay-specific threshold values in screening and confirmatory testing for primary aldosteronism","volume":"103","author":"Guo","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B58","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.tem.2005.02.006","article-title":"Plasma renin and aldosterone measurements in low renin hypertensive states","volume":"16","author":"Sealey","year":"2005","journal-title":"Trends Endocrinol Metab"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2009.09.018","article-title":"Pre-analytical and analytical considerations for the determination of plasma renin activity","volume":"410","author":"Brossaud","year":"2009","journal-title":"Clin Chim Acta"},{"key":"B60","article-title":"Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity","volume":"42","author":"Derkx","year":"1996","journal-title":"Clin Chem Jul"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/45.6.847","article-title":"Improved immunoradiometric assay for plasma renin","volume":"45","author":"Deinum","year":"1999","journal-title":"Clin Chem"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.116.08407","article-title":"Novel approach to establishing an aldosterone: renin ratio cutoff for primary aldosteronism","volume":"69","author":"Leung","year":"2017","journal-title":"Hypertension."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1500517","article-title":"Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass","volume":"150","author":"Unger","year":"2004","journal-title":"Eur J Endocrinology."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2010.009230","article-title":"A screening procedure for primary aldosteronism based on the Diasorin Liaison\u00ae automated chemiluminescent immunoassay for direct renin","volume":"47","author":"Dorrian","year":"2010","journal-title":"Ann Clin Biochemistry: Int J Lab Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32833857ad","article-title":"A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive renin","volume":"28","author":"Morganti","year":"2010","journal-title":"J Hypertension."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3109\/1354750X.2011.614015","article-title":"Two-site automated chemiluminescent assay for measurement of immunoreactive renin","volume":"16","author":"Gruson","year":"2011","journal-title":"Biomarkers."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1177\/1470320316657450","article-title":"Aldosterone\/direct renin concentration ratio as a screening test for primary aldosteronism: A meta-analysis","volume":"17","author":"Li","year":"2016","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.228","article-title":"Aldosterone\/direct renin concentration ratio versus aldosterone\/plasma renin activity for diagnosis of primary hyperaldosteronism: case presentation","volume":"5","author":"Shanik","year":"2021","journal-title":"J Endocrine Society."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.09078","article-title":"Rapid screening of primary aldosteronism by a novel chemiluminescent immunoassay","volume":"70","author":"Morimoto","year":"2017","journal-title":"Hypertension."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1530\/eje-17-0978","article-title":"Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms","volume":"178","author":"Heinrich","year":"2018","journal-title":"Eur J Endocrinology."},{"key":"B71","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular complications associated with primary aldosteronism","volume":"62","author":"Savard","year":"2013","journal-title":"Hypertension."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.117.10263","article-title":"Prevalence of cardiovascular disease and its risk factors in primary aldosteronism","volume":"71","author":"Ohno","year":"2018","journal-title":"Hypertension."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2018.01.006","article-title":"Targeted treatment of primary aldosteronism - The consensus of Taiwan Society of Aldosteronism","volume":"2","author":"Huang","year":"2018","journal-title":"J Formos Med Assoc"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2003.10.006","article-title":"Primary aldosteronism\u2014careful investigation is essential and rewarding","volume":"217","author":"Stowasser","year":"2004","journal-title":"Mol Cell Endocrinology."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.ej13-0060","article-title":"Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension","volume":"60","author":"Murase","year":"2013","journal-title":"Endocrine J"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1149","article-title":"The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling","volume":"90","author":"Tiu","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B77","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/01.hyp.0000038478.59760.41","article-title":"Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism","volume":"40","author":"Mulatero","year":"2002","journal-title":"Hypertension."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01613.x","article-title":"Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism","volume":"57","author":"Seifarth","year":"2002","journal-title":"Clin Endocrinology."},{"key":"B79","doi-asserted-by":"crossref","DOI":"10.1097\/HJH.0000000000002047","article-title":"Influence of antihypertensive drugs in the subtype diagnosis of primary aldosteronism by adrenal venous sampling","volume":"37","author":"Nagasawa","year":"2019","journal-title":"J Hypertension."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.0000040261.30455.b6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.119.14063","article-title":"Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit","volume":"75","author":"Burrello","year":"2020","journal-title":"Hypertension."},{"key":"B82","doi-asserted-by":"crossref","DOI":"10.1097\/HJH.0000000000002441","article-title":"Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension","author":"Parasiliti-Caprino","year":"2020","journal-title":"J Hypertension."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.109.139832","article-title":"Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism","volume":"55","author":"Rossi","year":"2010","journal-title":"Hypertension."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1992.262.5.F871","article-title":"Temporal pattern of renin and aldosterone secretion in men: effects of sodium balance","volume":"262","author":"Vieweg","year":"1992","journal-title":"Am J Physiol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1210\/jcem.80.1.7829626","article-title":"Increased disorderliness and amplified basal and pulsatile aldosterone secretion in patients with primary aldosteronism","volume":"80","author":"Siragy","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021476","article-title":"Variability in the renin\/aldosterone profile under random and standardized sampling conditions in primary aldosteronism","volume":"88","author":"Tanabe","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B87","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/HJH.0000000000001905","article-title":"Surprisingly low aldosterone levels in peripheral veins following intravenous sedation during adrenal vein sampling: implications for the concept of nonsuppressibility in primary aldosteronism","volume":"37","author":"Kline","year":"2019","journal-title":"J Hypertens"},{"key":"B88","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ajh\/hpaa151","article-title":"Variability of aldosterone measurements during adrenal venous sampling for primary aldosteronism","volume":"34","author":"Yozamp","year":"2021","journal-title":"Am J Hypertens"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1963","article-title":"Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism","volume":"101","author":"Baudrand","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.118.11064","article-title":"Hypertension in blacks","volume":"72","author":"Spence","year":"2018","journal-title":"Hypertension."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.120.16429","article-title":"Intraindividual variability of aldosterone concentrations in primary aldosteronism","volume":"77","author":"Yozamp","year":"2021","journal-title":"Hypertension."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.186239","article-title":"Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas","volume":"59","author":"Azizan","year":"2012","journal-title":"Hypertension. Mar"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.186478","article-title":"Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism","volume":"59","author":"Boulkroun","year":"2012","journal-title":"Hypertension."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.01733","article-title":"Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas","volume":"63","author":"Williams","year":"2014","journal-title":"Hypertension."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/srep11396","article-title":"Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population","volume":"5","author":"Wu","year":"2015","journal-title":"Sci Rep"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03346","article-title":"Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma","volume":"65","author":"Zheng","year":"2015","journal-title":"Hypertension. Mar"},{"key":"B97","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1210\/jc.2015-3284","article-title":"Clinical and steroidogenic characteristics of aldosterone-producing adenomas with ATPase or CACNA1D gene mutations","volume":"101","author":"Kitamoto","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B98","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/eje-21-0031","article-title":"GENETICS IN ENDOCRINOLOGY: Impact of race and sex on genetic causes of aldosterone-producing adenomas","volume":"185","author":"Nanba","year":"2021","journal-title":"Eur J Endocrinology."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Science."},{"key":"B100","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/ng.2550","article-title":"Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension","volume":"45","author":"Beuschlein","year":"2013","journal-title":"Nat Genet"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2695","article-title":"Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism","volume":"45","author":"Scholl","year":"2013","journal-title":"Nat Genet"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.119.14177","article-title":"Genetic, cellular, and molecular heterogeneity in adrenals with aldosterone-producing adenoma","volume":"75","author":"De Sousa","year":"2020","journal-title":"Hypertension."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3009","article-title":"Novel KCNJ5 mutations in sporadic aldosterone-producing adenoma reduce Kir3","volume":"100","author":"Cheng","year":"2015","journal-title":"4 membrane abundance. J Clin Endocrinol Metab"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147590","article-title":"Genetics of aldosterone-producing adenoma in korean patients","volume":"11","author":"Hong","year":"2016","journal-title":"PloS One"},{"key":"B105","article-title":"Comparison of cardiovascular complications in patients with and without KCNJ5 gene mutations harboring aldosterone-producing adenomas","volume":"24","author":"Kitamoto","year":"2014","journal-title":"J Atheroscl thrombosis."},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00666","article-title":"Prevalence and histopathological characteristics of KCNJ5 mutant aldosterone-producing adenomas in a multi-ethnic Malaysian cohort. Original research","volume":"10","author":"Mohideen","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa595","article-title":"Prevalence of somatic mutations in aldosterone-producing adenomas in Japanese patients","volume":"105","author":"Nanba","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2885","article-title":"Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas","volume":"97","author":"Taguchi","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000000708","article-title":"Prevalence and characterization of somatic mutations in chinese aldosterone-producing adenoma patients","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00097","article-title":"Prevalence of somatic KCNJ5 mutations in thai patients with aldosterone-producing adrenal adenomas","volume":"2","author":"Warachit","year":"2018","journal-title":"J Endocrine Society."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041926","article-title":"Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter","volume":"7","author":"Akerstrom","year":"2012","journal-title":"PloS One"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0321","article-title":"Novel somatic mutations and distinct molecular signature in aldosterone-producing adenomas","volume":"22","author":"Akerstrom","year":"2015","journal-title":"Endocr Relat Cancer."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-013-1093-2","article-title":"Outcome after surgery for primary hyperaldosteronism may depend on KCNJ5 tumor mutation status: a population-based study from Western Norway","volume":"398","author":"Arnesen","year":"2013","journal-title":"Langenbeck\u2019s Arch Surgery."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.114.03419","article-title":"Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma","volume":"64","author":"Fernandes-Rosa","year":"2014","journal-title":"Hypertension."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa367","article-title":"Biochemical, histopathological, and genetic characterization of posture-responsive and unresponsive APAs","volume":"105","author":"Guo","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.17348","article-title":"Single-center prospective cohort study on the histopathology, genotype, and postsurgical outcomes of patients with primary aldosteronism","volume":"78","author":"Meyer","year":"2021","journal-title":"Hypertension."},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01004","article-title":"Targeted molecular characterization of aldosterone-producing adenomas in white americans","volume":"103","author":"Nanba","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.12070","article-title":"Genetic characteristics of aldosterone-producing adenomas in blacks","volume":"73","author":"Nanba","year":"2019","journal-title":"Hypertension."},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12873","article-title":"Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype","volume":"83","author":"Scholl","year":"2015","journal-title":"Clin Endocrinology."},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169042","article-title":"Clinical translationality of KCNJ5 mutation in aldosterone producing adenoma","volume":"23","author":"Kitamoto","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2010","article-title":"Adrenocortical zonation in humans under normal and pathological conditions","volume":"95","author":"Nishimoto","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1505529112","article-title":"Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands","volume":"112","author":"Nishimoto","year":"2015","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00134","article-title":"Aldosterone-producing cell clusters frequently harbor somatic mutations and accumulate with age in normal adrenals","volume":"1","author":"Omata","year":"2017","journal-title":"J Endocrine Society."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11086","article-title":"Cellular and genetic causes of idiopathic hyperaldosteronism","volume":"72","author":"Omata","year":"2018","journal-title":"Hypertension. Oct"},{"key":"B125","doi-asserted-by":"crossref","DOI":"10.1291\/hypres.29.883","article-title":"Clinical characteristics of aldosterone-producing microadenoma, macroadenoma, and idiopathic hyperaldosteronism in 93 patients with primary aldosteronism","volume":"29","author":"Omura","year":"2006","journal-title":"Hypertens Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.117.028201","article-title":"Age-related autonomous aldosteronism","volume":"136","author":"Nanba","year":"2017","journal-title":"Circulation."},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.117.10391","article-title":"Aging and adrenal aldosterone production","volume":"71","author":"Nanba","year":"2018","journal-title":"Hypertension."},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.116.08952","article-title":"Continuum of renin-independent aldosteronism in normotension","volume":"69","author":"Baudrand","year":"2017","journal-title":"Hypertension."},{"key":"B129","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1038\/s41467-022-32896-8","article-title":"Identification of risk loci for primary aldosteronism in genome-wide association studies","volume":"13","author":"Le Floch","year":"2022","journal-title":"Nat Commun"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.06186","article-title":"Genotype-specific steroid profiles associated with aldosterone-producing adenomas","volume":"67","author":"Williams","year":"2016","journal-title":"Hypertension. Jan"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00738","article-title":"Aldosterone suppression by dexamethasone in patients with KCNJ5-mutated aldosterone-producing adenoma","volume":"103","author":"Inoue","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.12064","article-title":"18-oxocortisol synthesis in aldosterone-producing adrenocortical adenoma and significance of KCNJ5 mutation status","author":"Tezuka","year":"2019","journal-title":"Hypertension."},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab348","article-title":"Performance of the aldosterone to renin ratio as a screening test for primary aldosteronism","volume":"106","author":"Hung","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae145","article-title":"The spectrum of dysregulated aldosterone production: an international human physiology study","author":"Parksook","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B135","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-014-1658-0","article-title":"Primary aldosteronism and salt","volume":"467","author":"Funder","year":"2015","journal-title":"Pflugers Arch"},{"key":"B137","doi-asserted-by":"publisher","first-page":"e023813","DOI":"10.1161\/JAHA.121.023813","article-title":"Comparison of echocardiographic changes between surgery and medication treatment in patients with primary aldosteronism","volume":"11","author":"Ueda","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.123.21096","article-title":"Association of reversal of renin suppression with long-term renal outcome in medically treated primary aldosteronism","volume":"80","author":"Katsuragawa","year":"2023","journal-title":"Hypertension."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15006","article-title":"Serum aldosterone concentration, blood pressure, and coronary artery calcium: the multi-ethnic study of atherosclerosis","author":"Inoue","year":"2020","journal-title":"Hypertension."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.066389","article-title":"Subclinical primary aldosteronism and cardiovascular health: A population-based cohort study","volume":"149","author":"Hundemer","year":"2024","journal-title":"Circulation."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","article-title":"Observational study mortality in treated primary aldosteronism: the German Conn\u2019s registry","volume":"60","author":"Reincke","year":"2012","journal-title":"Hypertension. Sep"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpu154","article-title":"Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies","volume":"28","author":"Marzano","year":"2015","journal-title":"Am J Hypertension."},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-03773-9","article-title":"Practical consensus for the treatment and follow-up of primary aldosteronism: a multidisciplinary consensus document","volume":"85","author":"Araujo-Castro","year":"2024","journal-title":"Endocrine."},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-73-5-952","article-title":"Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism","volume":"73","author":"McKenna","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"B146","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7326\/0003-4819-72-1-9","article-title":"Suppressed plasma renin activity in essential hypertension","volume":"72","author":"Jose","year":"1970","journal-title":"Roles plasma volume Blood pressure sympathetic nervous system. Ann Intern Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1972.03650060041007","article-title":"The syndrome of essential hypertension and suppressed plasma renin activity","volume":"130","author":"Carey","year":"1972","journal-title":"Normalization Blood Pressure spironolactone. Arch Intern Med"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1979.03290280031022","article-title":"Renin profiling for diagnosis and treatment of hypertension","volume":"241","author":"Laragh","year":"1979","journal-title":"JAMA."},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020546","article-title":"The low-renin hypertension phenotype: genetics and the role of the mineralocorticoid receptor","volume":"19","author":"Baudrand","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinology."},{"key":"B152","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2265.2011.04243.x","article-title":"Spontaneous remission of idiopathic aldosteronism after long-term treatment with spironolactone: results from the German Conn\u2019s Registry","volume":"76","author":"Fischer","year":"2012","journal-title":"Clin endocrinology."},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","author":"Hundemer","year":"2018","journal-title":"Hypertension."},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-019-0244-4","article-title":"Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism","author":"Satoh","year":"2019","journal-title":"Hypertens Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.123.20536","article-title":"Who and how should we screen for primary aldosteronism","volume":"80","author":"Funder","year":"2023","journal-title":"Hypertension."},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(16)30272-8","article-title":"Primary aldosteronism as a public health issue","volume":"4","author":"Funder","year":"2016","journal-title":"Lancet Diabetes Endocrinology."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1372683\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T05:10:46Z","timestamp":1736831446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1372683\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":156,"alternative-id":["10.3389\/fendo.2024.1372683"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1372683","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"article-number":"1372683"}}